Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + R-CHOP in EBV-positive DLBCL (IVORY)
NCT02670616Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Samsung Medical Center. Started May 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02670616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670616.